Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
Status:
Terminated
Trial end date:
2021-07-14
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical
Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.